The phase 3 POIESIS trial is set to investigate navtemadlin as an add-on therapy to Jakafi in patients with JAK inhibitor-naive myelofibrosis.

Systemic sclerosis, or scleroderma, causes the hardening of skin and connective tissues. Often, the disease harms other ...

Novartis Canada is pleased to announce that Fabhalta® (iptacopan capsules) is now available across Canada for adult patients ...

When you're hungry, ghrelin hormone levels increase in your stomach and other parts of your body. Learn what causes its ...